VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2022 | CLL2-GiVe trial: ibrutinib, venetoclax and obinutuzumab in patients with TP53-mutated CLL

In this video, Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, shares some findings from the final analysis of the Phase II CLL2-GiVe trial (NCT02758665), which is evaluating the combination of ibrutinib, venetoclax and obinutuzumab in patients with chronic lymphocytic leukemia (CLL) with TP53 aberration. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Janssen, Roche, AbbVie, BeiGene, AstraZeneca: Research Funding; Janssen, Roche, AbbVie, BeiGene, AstraZeneca, MSD: Speakers Bureau; Beigene: Other: Travel Support; Janssen, AbbVie, Lilly, AstraZeneca, BeiGene, MSD: Consultancy.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter